Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.

Journal of experimental & clinical cancer research : CR - 18 Apr 2017

Jaruskova Monika, Curik Nikola, Hercog Rajna, Polivkova Vaclava, Motlova Eliska, Benes Vladimir, Klamova Hana, Pecherkova Pavla, Belohlavkova Petra, Vrbacky Filip, Machova Polakova Katerina

Abstract excerpt

BACKGROUND: Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for first-line treatment of patients with chronic myeloid leukemia. METHODS: In silico analysis using publicly available databases was done to select the SLC and ABC genes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation Rate

Share to Organic Cation Transport Proteins

Share to Solute Carrier Family 22 Member 5

Share to Symporters

Source

Open in PubMed Open full text

Identifiers

PMID: 28420426
DOI: 10.1186/s13046-017-0523-3
PMCID: PMC5395939

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.PMID 28420426Read ↗

Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.Semantic proximity Read ↗

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.Semantic proximity Read ↗

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.Semantic proximity Read ↗

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity Read ↗

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity Read ↗

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity Read ↗

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.Semantic proximity Read ↗

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Semantic proximity Read ↗

Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.Semantic proximity Read ↗

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity Read ↗

Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.Semantic proximity Read ↗

Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.